What to know about COVID-19 vaccines for small children

31/5/2022 9:45:00 PM

What to know about COVID-19 vaccines for small children

Covıd-19

What to know about COVID-19 vaccines for small children

Advisers to the US Food and Drug Administration are due to meet in June to decide on whether to recommend authorising Moderna Inc\u0027s vaccine for children below 6 years old, and Pfizer and BioNTech\u0027s COVID-19 vaccine for children below 5 years old. Here is a look at some of the factors expected to be co

Advisers to the US Food and Drug Administration are due to meet in June to decide on whether to recommend authorising Moderna Inc's vaccine for children below 6 years old, and Pfizer and BioNTech's COVID-19 vaccine for children below 5 years old.

Here is a look at some of the factors expected to be considered in this decision concerning the last age groups not yet covered by previous US regulatory authorisations for COVID-19 vaccines.HOW MANY DOSES ARE NEEDED?Moderna has filed with the FDA seeking authorisation for a two-dose regimen of its vaccine, called Spikevax, in children ages 6 months to 6 years old. Pfizer has not yet completed its FDA authorisation application but its clinical trial tested a three-dose course of the vaccine for children ages 6 months to under 5 years old.

Read more:
CNA »

Celine Dion reveals rare neurological disorder, cancels shows

OTTAWA — Pop diva Celine Dion on Thursday (Dec 8) tearfully revealed that she is suffering from Stiff-Person Syndrome, a rare neurological disorder that is affecting her singing, and said she would have to cancel or postpone a series of European shows. Read more >>

No!

Zero-Covid-19, big money: China's anti-virus spending boosts some sectors

China Covid-19 outbreak wanes, with curbs eased to boost economy

Asean economies shine as Covid-19 forces China to step backFake news Without china economic bullying, all businesses goes to Asia.

Where death rates rose the most during the Covid-19 pandemic

Weekly Covid-19 cases finally drop after 3 weeksSINGAPORE - The number of locally transmitted Covid-19 cases has been falling, with the weekly infection ratio now below one for the first time in three weeks. The week-on-week infection ratio - which refers to the ratio of community cases for the past week, over the week before - was at 0.98 on Sunday (May 29). The last time the...

North Korea rolls back lockdown, says Covid-19 flareup 'controlled'

LinkedIn Advisers to the US Food and Drug Administration are due to meet in June to decide on whether to recommend authorising Moderna Inc's vaccine for children below 6 years old, and Pfizer and BioNTech's COVID-19 vaccine for children below 5 years old.Copy to clipboard https://str.Copy to clipboard https://str.Copy to clipboard https://str.

Here is a look at some of the factors expected to be considered in this decision concerning the last age groups not yet covered by previous US regulatory authorisations for COVID-19 vaccines. HOW MANY DOSES ARE NEEDED? Moderna has filed with the FDA seeking authorisation for a two-dose regimen of its vaccine, called Spikevax, in children ages 6 months to 6 years old. The Chinese government, alone among major countries in vowing to eradicate the coronavirus within its borders, is on track to spend more than US$52 billion (S$71 billion) this year on testing, new medical facilities, monitoring equipment and other anti-Covid-19 measures, which will benefit as many as 3,000 companies, according to analysts. Pfizer has not yet completed its FDA authorisation application but its clinical trial tested a three-dose course of the vaccine for children ages 6 months to under 5 years old. Curbs on movement in several districts started to be loosened on Sunday after authorities said the outbreak was under control. Moderna plans to use a 25 microgrammes dose in that age group, lower than the 100 microgrammes used in the first two doses in adults and the 50 microgrammes used as a booster dose for non-immunocompromised adults. China aims to have Covid-19 testing facilities within 15-minutes' walk of everyone in its big cities and continues to impose mass testing at the slightest sign of an outbreak. In its clinical trial, Moderna administered the two doses 28 days apart.

Pfizer and BioNTech's vaccine, called Comirnaty, was tested as a 3 microgramme formulation in children below 5 years old, versus the 10 microgramme version used in children ages 5-11 and a 30 microgramme dose used for people ages 12 and older. The government is footing the bill for the vast majority of this, either by buying test kits or paying companies to do tests. The financial hub on Sunday rolled out a raft of measures to support the lockdown-hit economy, including allowing all manufacturing to restart from Wednesday. In their clinical trial, children were given the first two doses around three weeks apart, with the third dose administered at least three months after the second. Lower-dose versions are expected to reduce any side effects associated with the vaccines. First-quarter profit more than doubled for Hangzhou-based Dian Diagnostics Group, one of China's biggest medical test makers. HOW EFFECTIVE ARE THE VACCINES? For the Moderna vaccine in a clinical trial involving roughly 6,700 children, efficacy in preventing symptomatic infections among children 6 months to 2 years old was 43. Covid-19 test requirements will be loosened for people entering public places from June 1 as the city tries to restore a sense of normalcy after a two-month lockdown of its population of 25 million people.7 per cent, while efficacy was 37. Rival Adicon Holdings, which received about US$300 million of mostly government money for its Covid-19 tests over 2020 and 2021, according to the company's financial statements, has applied for an initial public offering on the Hong Kong stock exchange.

5 per cent for children 2-6 years old. There have not yet been enough symptomatic cases of COVID-19 among the children in the Pfizer-BioNTech trial to produce a final efficacy figure. China defends its"zero-Covid-19" policy as crucial to saving lives and preventing its healthcare system from being overrun. In Beijing, most public transport including buses, subways and taxis will resume in three districts including Chaoyang. An early analysis based on 10 symptomatic COVID-19 cases identified when the Omicron coronavirus variant was dominant suggested a vaccine efficacy of 80.3 per cent in the under-5 age group. The latest indicators show the country's economy has weakened sharply since March, as employment, consumer spending, exports and home sales have been hit by stringent lockdown measures that clogged highways and ports, stranded workers and shut factories. Pfizer and BioNTech plan to update those figures after at least 21 children in the trial get symptomatic COVID-19. Workers in some Beijing districts who were required to work from home previously will be allowed to return to their workplaces, and hotels and hostels in five districts on the city's outskirts will be permitted to reopen.

ARE THE VACCINES SAFE FOR CHILDREN? Safety data that included 1,678 children in Pfizer's trial showed that side effects were generally comparable to those observed in adults.8 per cent growth. Pfizer said it chose the lower-dose 3-microgramme version because of its safety profile. While it did not disclose specific safety data, it said the vaccine at this dosage was generally as safe as the placebo used in the study. Investors are uncertain how long the boom will last for companies like Dian, Adicon and Shanghai Runda, whose fortunes are closely tied to government spending. More On This Topic. Moderna's data showed that any side effects were mostly mild and moderate, with fever temperature similar to that experienced after vaccination with other paediatric vaccines. Fever greater than 104 degrees Fahrenheit was observed in 0. Stocks of both are down from the start of this year.

2 per cent of children ages 2-6 years and those ages 2 months to 2 years. Moderna said there were no reports of myocarditis or pericarditis, types of heart inflammation that have been linked to mRNA vaccines in rare cases among young men, in its trial."If the spread of the epidemic is well controlled and the epidemic prevention policy is adjusted, it may have a negative impact on the market demand for Covid-19 nucleic acid testing. The US Centers for Diseases Control and Prevention has said, based on data from the Pfizer vaccine, that rates of heart inflammation have been much lower in boys 5-11 years old than in adolescents and young men. WHY VACCINATE YOUNG CHILDREN? If the shots win regulatory authorisation in these age groups, parents will have to decide whether to get their children vaccinated."Epidemiologically and economically, it is unsustainable," he said. One question they might have is whether it is worth it, considering that many young children were infected during the Omicron wave.

Experts have said natural immunity wanes over time. Health authorities in Beijing and Shanghai did not respond to requests for comment. Data has shown that in older children and adults that those who had an infection and received a booster shot had the most protection against COVID-19, according to Dr Matthew Harris, a paediatric emergency medicine physician at Northwell Health in New York. Vaccines also protect against hospitalisations and deaths, said Harris, calling these important reasons why parents should consider vaccinating their children.4 billion citizens. The FDA has set June 15 as the date to review authorising the Moderna and Pfizer-BioNTech vaccines for these age groups. . Growth flattened out last year, but analysts expect it to pick up again this year and next.